Thus, we suggest that the overactivation of BCR-related genes such as CD79A, CD79B, and LAMTOR4 as the shared overexpressed genes among DLBCL, pSS peripheral, and SGs could be involved in pSS progression into lymphoma and probably be responsible for the failure of Rituximab therapy. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.